{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:50:50Z","timestamp":1787021450742,"version":"build-2736575974"},"reference-count":40,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:00:00Z","timestamp":1492646400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Bronchiectasis is a heterogeneous, chronic condition with many aetiologies.\u00a0It poses a significant burden on patients and healthcare practitioners and services.\u00a0Clinical exacerbations often result in reduced quality of life, increased rate of lung function decline, increased hospitalisation, and mortality. Recent focus in respiratory research, guidelines, and future management options has improved this clinical field in evidence-based practice, but further work and phase III clinical trials are required. This article aims to summarise and explore advances in management strategies in recent years and highlight areas of research and future focus.<\/ns4:p>","DOI":"10.12688\/f1000research.10613.1","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T10:55:07Z","timestamp":1492685707000},"page":"527","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["What\u2019s new in the management of adult bronchiectasis?"],"prefix":"10.12688","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2985-0984","authenticated-orcid":false,"given":"Usma","family":"Koser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2017,4,20]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"1446-62","DOI":"10.1183\/09031936.00119114","article-title":"Management of bronchiectasis in adults.","volume":"45","author":"J Chalmers","year":"2015","journal-title":"Eur Respir J."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"595-9","DOI":"10.1097\/MCP.0b013e328312ed8c","article-title":"Update on non-cystic fibrosis bronchiectasis.","volume":"14","author":"D Bilton","year":"2008","journal-title":"Curr Opin Pulm Med."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/thx.2010.142778","article-title":"British Thoracic Society guideline for non-CF bronchiectasis.","volume":"65","author":"M Pasteur","year":"2010","journal-title":"Thorax."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"186-93","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study.","volume":"47","author":"J Quint","year":"2016","journal-title":"Eur Respir J."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"1764-70","DOI":"10.1513\/AnnalsATS.201507-472OC","article-title":"Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity.","volume":"12","author":"S Lonni","year":"2015","journal-title":"Ann Am Thorac Soc."},{"key":"ref-6","first-page":"1-16","article-title":"British thoracic society quality standards for clinically significant bronchiectasis in adults July 2012.","volume":"4","author":"A Hill","year":"2012","journal-title":"Br Thorac Soc Rep."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"739-48","DOI":"10.1111\/resp.12528","article-title":"Aetiology of bronchiectasis in Guangzhou, southern China.","volume":"20","author":"W Guan","year":"2015","journal-title":"Respirology."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"843-9","DOI":"10.1183\/09031936.00003709","article-title":"Mortality in bronchiectasis: a long-term study assessing the factors influencing survival.","volume":"34","author":"M Loebinger","year":"2009","journal-title":"Eur Respir J."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"576-85","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The bronchiectasis severity index. An international derivation and validation study.","volume":"189","author":"J Chalmers","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1357-67","DOI":"10.1183\/09031936.00026313","article-title":"Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score.","volume":"43","author":"M Mart\u00ednez-Garc\u00eda","year":"2014","journal-title":"Eur Respir J."},{"key":"ref-11","first-page":"6-15","article-title":"Inflammation: a two-edged sword--the model of bronchiectasis.","volume":"147","author":"P Cole","year":"1986","journal-title":"Eur J Respir Dis Suppl."},{"key":"ref-12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006316.pub2","article-title":"Pneumococcal vaccines for children and adults with bronchiectasis.","author":"C Chang","year":"2007","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"250S-9","DOI":"10.1378\/chest.129.1_suppl.250S","article-title":"Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines.","volume":"129","author":"F McCool","year":"2006","journal-title":"Chest."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"181-9","DOI":"10.1159\/000375170","article-title":"Rehabilitation in patients with chronic respiratory disease other than chronic obstructive pulmonary disease: exercise and physical activity interventions in cystic fibrosis and non-cystic fibrosis bronchiectasis.","volume":"89","author":"C Burtin","year":"2015","journal-title":"Respiration."},{"key":"ref-15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008351.pub3","article-title":"Airway clearance techniques for bronchiectasis.","author":"A Lee","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"1602-11","DOI":"10.1513\/AnnalsATS.201506-333OC","article-title":"A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis.","volume":"12","author":"S Finch","year":"2015","journal-title":"Ann Am Thorac Soc."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"CD001289","DOI":"10.1002\/14651858.CD001289.pub2","article-title":"Mucolytics for bronchiectasis.","author":"M Wilkinson","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"661-7","DOI":"10.1016\/j.rmed.2011.12.021","article-title":"The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis.","volume":"106","author":"C Nicolson","year":"2012","journal-title":"Respir Med."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"1073-9","DOI":"10.1136\/thoraxjnl-2014-205587","article-title":"Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.","volume":"69","author":"D Bilton","year":"2014","journal-title":"Thorax."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1329-34","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.","volume":"113","author":"A O'Donnell","year":"1998","journal-title":"Chest."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"CD007525","DOI":"10.1002\/14651858.CD007525.pub3","article-title":"Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis.","author":"S Pizzutto","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"CD010327","DOI":"10.1002\/14651858.CD010327.pub2","article-title":"Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis.","author":"V Goyal","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"461-8","DOI":"10.1378\/chest.11-0180","article-title":"Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis.","volume":"141","author":"M Mart\u00ednez-Garc\u00eda","year":"2012","journal-title":"Chest."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"455-63","DOI":"10.1016\/S2213-2600(14)70050-5","article-title":"Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial.","volume":"2","author":"P Mandal","year":"2014","journal-title":"Lancet Respir Med."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"524-33","DOI":"10.1016\/j.rmed.2012.12.009","article-title":"Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.","volume":"107","author":"R Stockley","year":"2013","journal-title":"Respir Med."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"e90047","DOI":"10.1371\/journal.pone.0090047","article-title":"Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis.","volume":"9","author":"Y Gao","year":"2014","journal-title":"PLoS One."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"1251-9","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.","volume":"309","author":"J Altenburg","year":"2013","journal-title":"JAMA."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1260-7","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.","volume":"309","author":"D Serisier","year":"2013","journal-title":"JAMA."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"660-7","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.","volume":"380","author":"C Wong","year":"2012","journal-title":"Lancet."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1001\/jama.2015.11206","article-title":"Spreading US Macrolide Resistance.","volume":"314","year":"2015","journal-title":"JAMA."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"738-49","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.","volume":"2","author":"A Barker","year":"2014","journal-title":"Lancet Respir Med."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"975-82","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.","volume":"189","author":"C Haworth","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics8010006","article-title":"Development of Liposomal Ciprofloxacin to Treat Lung Infections.","volume":"8","author":"D Cipolla","year":"2016","journal-title":"Pharmaceutics."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"OA272","DOI":"10.1183\/13993003.congress-2016.OA272","article-title":"LATE-BREAKING ABSTRACT: RESPIRE 1: Ciprofloxacin DPI 32.5 mg bd administered 14 day on\/off or 28 day on\/off vs. placebo for 48 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFB).","volume":"48","author":"A De Soyza","year":"2016","journal-title":"Eur Respir J."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"812-7","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.","volume":"68","author":"D Serisier","year":"2013","journal-title":"Thorax."},{"key":"ref-36","first-page":"p.2016","article-title":"Orbit-3 And Orbit-4: Design Of A Phase 3 Program To Investigate Safety And Efficacy Of Pulmaquin\u00ae In Non-Cystic Fibrosis Bronchiectasis (ncfbe) Patients Chronically Colonized With Pseudomonas Aeruginosa (pa).","volume":"193","author":"D Bilton","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-37","first-page":"A1775-A1775","article-title":"ORBIT-3 And ORBIT-4: Design Of A Phase 3 Program To Investigate Safety And Efficacy Of Pulmaquin\u00ae In Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients Chronically Colonized With Pseudomonas Aeruginosa (PA)","volume":"193","author":"A O'Donnell","year":"2016"},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1465-9921-15-44","article-title":"The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis--a randomised controlled trial.","volume":"15","author":"A Lee","year":"2014","journal-title":"Respir Res."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2466-13-21","article-title":"Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis.","volume":"13","author":"A Nicolini","year":"2013","journal-title":"BMC Pulm Med."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"1107-15","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.","volume":"41","author":"R Wilson","year":"2013","journal-title":"Eur Respir J."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/6-527\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-527\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-527\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T11:13:40Z","timestamp":1553253220000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/6-527\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,20]]},"references-count":40,"URL":"https:\/\/doi.org\/10.12688\/f1000research.10613.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.11437.r22046","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.11437.r21861","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,20]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/6-527\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.11437.r22046, Miguel \u00c1ngel Martinez-Garc\u00eda, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Valencia, Spain, 20 Apr 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-527\/v1#referee-response-22046","order":0,"name":"referee-response-22046","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.11437.r21861, Diana Bilton, Michael Loebinger, Department of Respiratory Medicine, Royal Brompton Hospital, London, UK, 20 Apr 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-527\/v1#referee-response-21861","order":1,"name":"referee-response-21861","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).","order":0,"name":"copyright-info","label":"Copyright"}]}}